Form 4: Revolution Medicines General Counsel Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Jeff Cislini, General Counsel of Revolution Medicines, Inc., sold 1,912 shares of common stock for approximately $75,760 under a pre-arranged 10b5-1 trading plan.
Summary
- Jeff Cislini, the General Counsel of Revolution Medicines, Inc. (RVMD), executed a sale of company common stock.
- The transaction involved the disposition of 1,912 shares of common stock.
- The shares were sold at a weighted average price of $39.6108 per share, with individual trades ranging from $39.26 to $40.05.
- The total value of the shares sold was approximately $75,760.
- This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Cislini on March 13, 2025.
- Following this transaction, Mr. Cislini directly beneficially owns 54,093 shares of Revolution Medicines common stock, which includes 49,054 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral. A routine insider sale under a 10b5-1 plan is generally not indicative of negative sentiment towards the company, as it is often for personal financial planning and pre-scheduled.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
Insider transactions, particularly sales under Rule 10b5-1 plans, are common occurrences across all industries, including biotechnology. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against insider trading allegations and facilitating personal financial planning.
Stakeholder Impact
- Shareholders: A minor insider sale under a 10b5-1 plan typically has minimal direct impact on the company's share price or long-term value. It is a routine disclosure for transparency.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Date Reporting Person adopted the 10b5-1 trading plan. |
| 06/20/2025 | Date of the reported transaction (sale of common stock). |
| 06/23/2025 | Date the Form 4 filing was signed. |
Keywords
Revolution Medicines, RVMD, SEC Form 4, Insider Trading, Stock Sale, Jeff Cislini, General Counsel, 10b5-1 Plan, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.